Table 5.

Changes of outcomes from baseline by the compliance level in the intervention group.

Outcome			Compliance (n=48), mean (SD)							P value
			A: < 70% (n=15)		B: 70%-90% (n=18)		C: ≥90% (n=15)
Weight (kg)
	3 months	–1.5 (3.97)		–2.2 (3.27)		–2.4 (1.80)		.37
	6 months	–0.6 (2.22)		–1.8 (2.91)		–2.2 (2.92)		.01 (A<C)
BMI (kg/m2)
	3 months	–0.5 (1.37)		–0.8 (1.13)		–0.9 (0.69)		.26
	6 months	–0.2 (0.77)		–0.7 (1.05)		–0.8 (1.02)		.005 (A<C)
Liver fat score
	6 months	–4.4 (23.90)		–6.8 (30.09)		–24.5 (34.00)		.002 (A=B<C)
ASTa (IU/L)
	6 months	–1.8 (6.35)		–0.3 (12.95)		–12.1 (13.81)		<.001 (A=B<C)
ALTb (IU/L)
	6 months	–12.2 (12.36)		–3.6 (15.75)		–8.8 (19.68)		.03 (A>B)
ɣ-GTc
	6 months	–11.3 (21.89)		–1.4 (15.47)		–28.6 (55.21)		.001 (B<C)
Self-management
	3 months	<0.1 (0.31)		0.3 (0.48)		0.6 (0.38)		<.001 (A<B<C)
	6 months	<0.1 (0.58)		0.4 (0.63)		0.6 (0.53)		<.001 (A<B<C)
Knowledge
	3 months	0.4 (1.30)		0.2 (1.42)		1.0 (1.36)		.008 (B<C)
	6 months	0.2 (1.70)		–0.2 (1.50)		0.9 (0.96)		.001 (A=B<C)
Self-efficacy
	3 months	<0.1 (0.79)		–0.2 (1.28)		0.1 (1.25)		.35
	6 months	0.4 (0.83)		0.3 (1.06)		0.2 (1.41)		.73
Fatigue
	3 months	0.2 (1.57)		–0.2 (1.20)		–0.4 (1.35)		.08
	6 months	–0.1 (1.33)		–0.8 (1.39)		–0.8 (1.51)		.03 (A<B=C)
Depression
	3 months	–0.2 (3.88)		–1.3 (3.53)		–1.4 (3.94)		.22
	6 months	–0.9 (2.59)		–1.8 (5.01)		–2.6 (3.27)		.10
Quality of life
	3 months	0.7 (6.81)		4.8 (8.77)		5.5 (8.15)		.008 (A<B=C)
	6 months	3.8 (7.63)		8.7 (15.12)		7.3 (12.26)		.13

^aAST: aspartate aminotransferase.

^bALT: alanine transaminase.

^cɣ-GT: gamma-glutamyl transferase.